Cures Within Reach

02/19/2026

Our funding is now supporting an ongoing Phase II trial led by Dr. Chinwe Chukwudi at University of of Nigeria: Treating Cutaneous Leishmaniasis with a Topical Antiseptic in Nigeria. Read more here: https://www.cureswithinreach.org/2026/01/26/treating-cutaneous-leishmaniasis-with-a-topical-antiseptic-in-nigeria/

Leishmaniasis is a neglected tropical disease caused by parasites transmitted through sandfly bites, affecting 1 to 2 million people and leading to thousands of deaths each year. Treatment remains a challenge worldwide due to variability of parasite species across regions and limited efficacy/access...

02/17/2026

Spread the word about our clinical trial funding! Our 2026 LMIC and Chicago-focused RFPs are now accepting LOI submissions. Read about these and other RFPs coming soon plus meet our Feb Researcher Spotlight: Dr. Austin Wesevich of The University of Chicago in our Feb newsletter: https://bit.ly/4cw4uu3​​

02/11/2026

Exciting News! We selected 7 new LMIC-based clinical repurposing trials in 2025 to advance therapies for patients facing high disease burdens using generic, available medicines. With support from Coefficient Giving, these trials are led by researchers in Bangladesh, India, Kenya, Nigeria and Tanzania plus funding for engaging community organizations. This brings our LMIC portfolio to 26 trials with more to be selected in 2026 from our now open funding opportunity RFP, all to strengthen local research capacity and accelerating equitable access to treatment. Learn more: https://www.cureswithinreach.org/2026/02/11/press-release-cwr-selected-seven-more-clinical-trials-to-address-factors-that-lead-to-high-disease-burden-in-low-and-lower-middle-income-countries/

01/30/2026

Our 2025 Annual Report is live: celebrating 20 years, $17mil in catalytic follow-on funding and 16 trials started. Help spread the word bit.ly/CWRAR25. Together, we are turning existing medicines into new possibilities for patients in need.

01/20/2026

Our funding is now supporting this already ongoing led by Dr. Jackton Omoto at Maseno university: Improving Pre-Cancerous Lesion Treatment Among HIV-Positive Women in Kenya - our 11th in women’s health. Read more: www.cureswithinreach.org/2025/12/10/i...

01/16/2026

A record 145 volunteer grant reviewers helped us select 17 trials in 2025. Read more and meet our Jan Researcher Spotlight: Dr. Fahafahantsoa Rapelanoro Rabenja of University of Antananarivo in our Jan newsletter: https://bit.ly/3LwneyI

12/12/2025

Our funding is now supporting an ongoing Phase II trial led by Dr. Olufemi Idowu at Lagos State University: Helping Recovery After Traumatic Brain Injury with Vitamin D3 in Nigeria. Read more here: https://www.cureswithinreach.org/2025/11/11/helping-recovery-after-traumatic-brain-injury-with-vitamin-d3-in-nigeria/

12/11/2025

We selected 7 more LMIC-based clinical trials in 2025 to impact high disease burden, thanks to Coefficient Giving. Read more and meet our Dec Researcher Spotlight: Dr. Sarah Keim of Nationwide Children's Hospital in our Dec enewsletter: https://bit.ly/4pvgWxL

11/20/2025

Our funding is now supporting our 9th blood cancer trial – an ongoing Phase II trial at Moffitt Cancer Center led by Dr. Zhuoer Xie: Using Empagliflozin to Treat Clonal Hematopoiesis. Read more at https://www.cureswithinreach.org/2025/10/28/using-empagliflozin-to-treat-clonal-hematopoiesis/.

11/17/2025

Meet our November Researcher Spotlight: Dr. Victoria Lee of University of Illinois Chicago - Translating Research Into Clinical Practice in Rhinology. Read more at https://www.cureswithinreach.org/2024/04/17/treating-chronic-sinus-inflammation-with-probiotic-sinus-wash/

11/11/2025

Today we celebrate and our goal to advance treatment options that improve Veterans’ health. Explore our Veterans portfolio, a planned 2026 RFP and our Veterans’ stakeholders in our November enewsletter: https://bit.ly/4p4e76m

10/30/2025

Reflecting on our past 20 years, Cures Within Reach is more excited than ever for the future: fast-track impact for patients with unsolved diseases funding using already approved therapies to build clinical evidence.